Dogwood Therapeutics to Participate at the Maxim Growth Summit 2025

Rhea-AI Summary

Dogwood Therapeutics (Nasdaq:DWTX) announced that CEO Greg Duncan will participate at the Maxim Growth Summit on October 22–23, 2025 at the Hard Rock Hotel in New York City.

Mr. Duncan will be available for one-on-one meetings with institutional investors and will meet with senior Maxim analysts during the event. For agenda and registration details, visit www.maximgrp.com/2025-growth-summit.

ATLANTA, GA, GA / ACCESS Newswire / October 14, 2025 / Dogwood Therapeutics, Inc. (Nasdaq:DWTX) (the "Company"), a development-stage biotechnology company developing new medicines to treat pain and neuropathic disorders, today announces that Greg Duncan, Chief Executive Officer will participate at the Maxim Growth Summit presented by Maxim Group LLC. The Summit is being held on October 22 - 23, 2025 at the Hard Rock Hotel in New York City.

Mr. Duncan will be available for one-on-one meetings with institutional investors and will also meet with senior Maxim analysts throughout the event.

For more information and a complete agenda of the Maxim Growth Summit, please visit www.maximgrp.com/2025-growth-summit.

About Dogwood Therapeutics

Dogwood Therapeutics (Nasdaq:DWTX) is a development-stage biopharmaceutical company focused on developing new medicines to treat pain and fatigue-related disorders. The Dogwood research pipeline includes two separate mechanistic platforms with a non-opioid analgesic program and an antiviral program. The proprietary, non-opioid, Na_V 1.7 analgesic program is centered on our lead development candidate, Halneuron^®, which is a highly specific voltage-gated sodium channel modulator, a mechanism known to be effective for reducing pain transmission. In clinical studies, Halneuron^® treatment has demonstrated pain reduction in pain related to general cancer and in pain related to chronic chemotherapy-induced neuropathic pain ("CINP"). Interim data from the ongoing Halneuron^® Phase 2 CINP study are expected in Q4 of 2025.

Dogwood is also developing SP16 IV, an LRP1 agonist with potential to treat neuropathy and prevent or repair nerve damage following chemotherapy. SP16 acts as an LRP1 agonist that in turn provides alpha-1-antitrypsin-like activity. Consistent with alpha-1-antitrypsin anti-inflammatory and immunomodulatory actions, SP16 preclinically demonstrated anti-inflammatory (analgesic) action via potential reductions in IL-6, IL-8, IL1B and TNF-alpha levels, as well as potential to repair damaged tissue via increases in pAKT and pERK that regulate fundamental processes like growth, proliferation and survival. The forthcoming SP16 IV Phase 1b CINP trial, which has been fully funded by the National Cancer Institute, is projected to commence enrolling patients in the first half of 2026.

For more information, please visit www.dwtx.com.

Forward-Looking Statements:

Statements in this press release contain "forward-looking statements," within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "suggest," "target," "aim," "should," "will," "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Dogwood's current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including risks related to the completion, timing and results of current and future clinical studies relating to Dogwood's product candidates. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled "Risk Factors" in the Annual Report on Form 10-K for the year ended December 31, 2024, which has been filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Dogwood undertakes no duty to update such information except as required under applicable law.

Investor Relations:

CORE IR
(516) 222-2560
IR@dwtx.com

SOURCE: Dogwood Therapeutics, Inc.

View the original press release on ACCESS Newswire

FAQ

When will Dogwood Therapeutics (DWTX) CEO Greg Duncan speak at the Maxim Growth Summit 2025?

Greg Duncan will participate during the October 22–23, 2025 Maxim Growth Summit in New York City.

Where is the Maxim Growth Summit 2025 that Dogwood Therapeutics (DWTX) will attend?

The summit is being held at the Hard Rock Hotel, New York City on October 22–23, 2025.

Will Dogwood Therapeutics (DWTX) management meet with investors at the Maxim Growth Summit 2025?

Yes. CEO Greg Duncan will be available for one-on-one meetings with institutional investors and will meet Maxim analysts.

How can investors access the Maxim Growth Summit 2025 agenda for Dogwood Therapeutics (DWTX)?

Investors can view the full agenda and event details at www.maximgrp.com/2025-growth-summit.

Is Dogwood Therapeutics (DWTX) presenting a public session at the Maxim Growth Summit 2025?

The announcement states CEO participation and investor meetings; check the summit agenda at the Maxim site for any public presentation times.

Who from Dogwood Therapeutics (DWTX) will attend the Maxim Growth Summit 2025?

The company announced that Greg Duncan, Chief Executive Officer, will participate and meet with investors and Maxim analysts.